New treatment possibilities in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 29, Issue 2, 2000, Pages 73-84

  Førre, Øystein ^a   Haugen, Margaretha ^a   Hassfeld, Wolfgang G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anti cytokines; Cytokines; Enbrel; Gene therapy; Monoklonal antibodies; Remicade; Stem cell transplantation

Indexed keywords

ANTIRHEUMATIC AGENT; CD4 ANTIGEN; CD5 ANTIGEN; CD52 ANTIGEN; CD7 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; RAPAMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNE DISEASE; GENE THERAPY; HUMAN; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION;

EID: 0033947306     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097400750001860     Document Type: Review

References (113)

1. 1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:712-22.
2. 2. Førre Ø, Thoen J, Lea T, Dobloug JH, Mellbye OJ, Solheim BG, et al. In situ characterization of mononuclear cells in rheumatoid tissues using monoclonal antibodies. No reduction in T8-positive Cells or Augmentation in T4 positive cells. Scand J Immunol 1982;16:315-9.
3. 3. Ploski R, Mellbye OJ, Skjold Rønningen K, Førre Ø, Thorsby E. Seronegative and weakly seropositive rheumatoid arthritis differ from clearly seropositive rheumatoid arthritis in HLA class II associations. J Rheumatol 1994;28:1397-402.
4. 4. Waalen K, Førre Ø, Teigland J, Natvig JB. Human rheumatoid synovial and normal blood dendritic cells as antigen presenting cells - comparison with autologous monocytes. Clin Exp Immunol 1987;70:1-9.
5. 5. Jalkanen S. Leukocyte-endothelial cell interaction and the control of leukocyte migration into inflamed synovium. Springer Semin Immunopathol 1989;11:187-98.
6. 6. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999;6:S254.
7. 7. Wacholtz MC, Patel SS, Lipsky PE. Leukocyte function-associated antigen I is an activation molecule for human T cells. J Exp Med 1989;170:431-8.
8. 8. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998;7: 1141-51.
9. 9. Folkman J, Ausprunk D, Langer R. Connective tissue, small blood vessels and capillaries. In: Kelley WN, ed. Textbook of Rheumatology edn. 2. Philadelphia: WB Saunders 1985:197-210.
10. 10. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:44-7.
11. 11. Polverinin PJ. The pathophysiology of angiogenesis Crit Rev Oral Biol Med 1995;6:230-47.
12. 12. Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36:307-18.
13. 13. Van der Lubbe PA, Reiter C, Breedveld FC, Krüger K, Schattenkirchner M, Sanders ME, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993;6:1375-9.
14. 14. Choy EHS, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joints is associated with clinical improvement: Implications for the development of immunotheraputic dosing regiments. Arthritis Rheum 1996;39:52-6.
15. 15. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-8.
16. 16. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
17. 17. Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody: long-term followup of CD4 + T cell counts. Arthritis Rheum 1994;37:834-8.
18. 18. Moreland LW, Bucy RP, Knowles RW, Wacholtz MC, Haverty TP, Koopman WJ. Treating rheumatoid arthritis with a non-depleting anti-CD4 monoclonal antibody (MAb) (abstract). Investing Med 1995;43 Suppl 2:362A.
19. 19. Panayi GS, Choy EHS, Connolly DJA, Regan T, Manna VK, Rapson N, et al., T cell hypothesis in rheumatoid arthritis tested by humanized non-depleting anti-CD4 monoclonal antibody treatment I: suppression of disease activity and acute phase response. Arthritis Rheum 1996;39 Suppl 9:S244.
20. TM IDEC-CE9.1 - an anti-CD4 monoclonal antibody in RA. Arthritis Rheum 1994;37 Suppl 9:S337.
21. 21. Issacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
22. 22. Matteson EL, Yocum DE, Clair EW. St, Achkar AA, Thakor MS, Jacobs MR, et al. Treatment of active refractory rheumatoid arthritis with humanized monocolonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995;38:1187-93.
23. 23. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz, Sturrock RD, et al. CAMPATH-H1, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 1995;38:1589-94.
24. 24. Choy EH, Kingsley GH, Panayi GS. T cell regulation. In: Brooks PM Furst DE, eds. Innovative Treatment Approaches for Rheumatoid Arthritis. London: Baillière's. Clin Rheumatol ; 1995:653-71.
25. 25. Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with CAMPATH-1H. Arthritis Rheum 1995;38:254-8.
26. 26. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 1993;36:620-30.
27. 27. Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, Clair EW. St, Mattesen EL, et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1102-8.
28. 28. Kirkham BW, Thien F, Pelton BK, Pitzalis C, Amlot P, Denman AM. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348-52.
29. 29. Waalen K, Førre Ø, Linker-Israeli M, Thoen J. Evidence of an activated T cell system with augmented turnover of interleukin-2 in rheumatoid arthritis - stimulation of human T lymphocytes by dendritic cells as a model for rheumatoid T cell activation. Scand J Immunol 1987;25:367-73.
30. 30. Kyle V, Coughlan RJ, Tighe H, Waldmann H, Hazleman BL. Beneficial effects of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989;48:428-9.
31. 31. Sewell KL, Parker KC, Woodworth TG, Reuben J, Swartz W, Trentham DE. DAB486IL-2 fusion toxin in refractory arthritis. Arthritis Rheum 1993;36:1223-33.
32. 32. Moreland LW, Sewell KL, Trentham DE, Bucy RP, Sullivan WF, Schrohenloher RE, et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis: a double-blind placebo-controlled trial with open-label extension. Arthritis Rheum 1995;38:1177-86.
33. 389IL-2 administrated up to four times a year to patients with rheumatoid arthritis. Arthritis Rheum 1994;37 Suppl 9:S341.
34. 34. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83:7443-6.
35. 35. Myers LK, Stuart JM, Seyer JM, Kang AH. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989;170:1999-2010.
36. 36. Miller EJ. Biochemical characteristics and biological significance of the genetically distinct collagens. Mol Cell Biochem 1976;13:165-92.
37. 37. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;19:335 43.
38. 38. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo D, Sewell KL, et al. Effects of oral administration of type II collagen on RA. Science 1993;261:1727-30.
39. 39. Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Huge W, et al. Oral type II collagen treatment in early RA: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996;39:41-51.
40. 40. Barnett ML, Kremer JM, Clair EW. St, Clegg DO, Furst D, et al. Treatment of rheumatoid arthritis with oral type II collagen. Arthritis Rheum 1998;41:290-7.
41. 41. Zagon G, Tumang JR, Li Y, Friedman SM, Crow MK. Increased frequency of Vβ17 -positive T cells in patients with rheumatoid arthritis. Arthritis Rheum 1994:1431-40.
42. 42. Goronzy JJ, Bartz JJ, Bartz-Bazzanella P, Hu W, Jendro MC, Walser-Kuntz DR, et al. Dominant clonotypes in the repertoire of peripheral CD4+T cells in rheumatoid arthritis. J Clin Invest 1994;94:2068-76.
43. 43. Howell MD, Diveley JP, Lundeen KA, Esty A, Winters ST, Carlo DJ, et al. Limited T-cell receptor B-chain heterogenity among interleukin-2 receptor-positive synovial T cell suggests a role for superantigen in rheumatoid arthritis. Proc Natl Acad Sci USA 1991;88:10921-5.
44. 44. Williams WV, Kieber-Emmons T, Fang Q, Von Feldt J, Wang B, Ramnujam T, et al. Conserved motifs in rheumatoid arthritis synovial tissue T-cell receptor beta chains. DNA Cell Biol 1993;12 425:34.
45. 45. Sioud M, Kjeldsen-Kragh J, Quayle A, Wiker HG, Sörskaar D, Natvig JB, et al. Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatoid patients and Vβ usage by specific synovial T cell lines and fresh T cells. Scand J Immunol 1991;34:803-12.
46. 46. Moreland LW, Morgan EE, Adamson TC, Fronek Z, Calabrese LH, et al. T cell receptor peptide vaccination in rheumatoid arthritis. Arthritis Rheum 1998;41:1919-29.
47. 47. Van Laar JM, Miltenburg AMM, Verdonk MJA, Leow A, Elferink BG, Daha MR, et al. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. J Autoimmun 1993;6:159-67.
48. 48. Kingsley GH, Verwilghen J. T cell vaccinations in humans. Clin Exp Rheumatol 1993;11:63-4.
49. 49. Lohse AW, Bakker NPM, Hermann E, Poralla T, Jonker M, Meyer ZUM, et al. Induction of an anti-vaccine response by T-cell vaccination in non-human primates and humans. J Autoimmun 1993 1993;1 121:30.
50. 50. Combe B, Cosso B, Clot J, Bonneau M, Sany J. Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 1985;78:920-8.
51. 51. Moynier M, Cosso B, Brochier J, Clot J. Identification of class II HLA alloantibodies in placenta-eluted gammaglobulins used for treating rheumatoid arthritis. Arthritis Rheum 1987;30:375-81.
52. 52. Pratt W, Heck L, Moreland L, Koopman W, Parkhill T, Pratt G, et al., Safety and immunogenicity of a single intramuscular injection of a synthetic HLA-DR4/1-peptide vaccine with alum adjuvant in rheumatoid arthritis patients. Arthritis Rheum 1995;38 Suppl 9:S281.
53. 53. Adorini L, Sinigaglia F. Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today 1997;18:209-11.
54. 54. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis. Arthritis Rheum 1997;40:397-409.
55. 55. Saxne T, Palladino MA jr. , Heinegrad D. Detection of tumor necrosis factor alpha, but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
56. 56. Häuselmann HJ, Flechtenmacher J, Michal L, Thonar EJ-MA, Shinmei M, Kuettner KE, et al. The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum 1996;39:478-88.
57. 57. Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, et al. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm 1996;47:27-38.
58. 58. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994:2762-6.
59. 59. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
60. 60. Elliot MJ, Maini RN, Feldman M, Kalden JR. , Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
61. 61. Mojcik CF, Shevach EM. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997;40:991-1004.
62. 62. Maini RN, Breedeveld FC, Kalden JR, Smolen JS, Davis D, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
63. 63. Baumgartner S, Moreland LW, Schiff MH, Tindall E, Fleischmann RM, Weaver A, et al. Double-blind, placebo-controlled trial of tumor necrosis factor receptor fusion protein (TNFR:Fcc) in active rheumatoid arthritis. J Invest Med 1996;44:235A.
64. 64. Cutolo M, Kirkham B, Bologna C, Sany J, Scott D, Brooks P, et al. Loading/maintenance doses approach to neutralization of TNF by lenercept (TNFR55-IgG1, Ro-45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a double-blind placebo-controlled phase II trial. Arthritis Rheum 1996;39 Suppl:S243.
65. 65. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-8.
66. 66. Sioud M, Natvig JB, Förre Ö. Preformed ribozyme destroys tumor necrosis factor mRNA in human cells. J Mol Biol 1992;223:831-5.
67. 67. Hopkins SJ, Humphreys M, Jayson MIV. Cytokines in synovial fluid I: the presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988;72:422-7.
68. 68. North J, Situnayake RD, Tikley M. Interleukin-1 beta, hand and foot bone mineral content and the development of joint erosions in rheumatoid arthritis. Ann Rheum Dis 1994;53:543-6.
69. 69. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991;5:2567-74.
70. 70. Drevlow B, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM. Phase I study of recombinant human interleukin-1 receptor (rhu IL-IR) administrered intra-articularly in active rheumatoid arthritis. Arthritis Rheum 1993;36 Suppl 9:S39.
71. 71. Drevlow BE, Lovis R, Haag MA. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996;39:257-65.
72. 72. Arend WP. Interleukin-1 receptor antagonists. Adv Immunol 1993;54:167-227.
73. 73. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 recptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
74. 74. Champion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, The IL-IRa Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
75. 75. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-I receptor antagonist. Arthritis Rheum 1998;41:2196-204.
76. 76. Van Roon JAG, van Roy JLA, Gmelig-Meyling FHJ, Lafeber FPJG, Bijlsma JWJ. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin 4. Arthritis Rheum 1996;39:829-35.
77. 2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclooxygenase II, but not of cyclo-oxygenase I. Ann Rheum Dis 1996;55:375-82.
78. 78. Isomäki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1693-702.
79. 79. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996;26:2399-403.
80. 80. Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, et al. Double-blind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989;32:964-73.
81. 81. Lemmel EM, Gaus W, Hofschneider PH. Multicenter double-blind trial of inlerferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1991;34:1621-2.
82. 82. Veys EM, Mielants H, Verbruggen G, Grosclande JP, Meyer W, Galazka A, et al. Interferon gamma in RA: a double-blind study comparing human recombinant interferon gamma with placebo. J Rheumatol 1988;15:570-4.
83. 83. Machold KP, Neumann K, Smolen JS. Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo-controlled study. Ann Rheum Dis 1992;51:1039-43.
84. 84. Kavanaugh AR, Davis LS, Jain RI, Nicholos LA, Norris SH, Pe L. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercelluar adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996;23 1338:44.
85. 85. Wicks I, Cooley H, Szer J. Autologous hemopoietic stem cell transplantation: a possible cure for rheumatoid arthritis? Arthritis Rheum 1997;40:1005-11.
86. 86. Tyndall A, Grathwohl A. Bone marrow transplantation in the treatment of autoimmune diseases. Br J Rheumatol 1997;36:1-5.
87. 87. Roessler FJ, Allen ED, Wilson JM, Hartman JW, Davidson BL. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993;92:1085-92.
88. 88. Bandara G, Mueller GM, Galea-Lauri J, Tindall MH, Georgescu HI, Suchaneek MK, et al. Intraarticular expression of biologically active interleukin-1 receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993;90:10764-8.
89. 89. Ryan ME, Greenwald RA, Golub LM. Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1996;8:238-47.
90. 90. Gravallese EM, Handel ML, Coblyn J, Andcrson RJ, Sperling RI, Karlson EW, et al. N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Arthritis Rheum 1996;39:1021-6.
91. 91. Golub LM, Wolff M, Lee HM, McNamara TF, Ramamurthy NS, Zambon J, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular lung and from other mammalian sources. J Periodontal Res 1985;20:12-23.
92. 92. Sasaki T, Ramamurthy NS, Golub LM. Tetracycline administration increases collagen synthesis in osteoblasts of streptozotocin-induced diabetic rats: a quantitative autoradio-graphic study. Calcif Tissue Int 1992;50:411-9.
93. 93. Breedveld FC, Dijkmans BAC, Mattie H. Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 1990;7:43-6.
94. 94. Tillcy BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis: a 48-week double blind, placebo-controlled trial. Ann Intern Med 1995;122:81-9.
95. 95. Peltonen R, Kjeldsen-Kragh J, Haugen M, Tuominen J, Toivanen P, Förre Ö, et al. Changes of faecal flora in rheumatoid arthritis during fasting and one-year vegetarian diet. Br J Rheumatol 1994;33:638-43.
96. 96. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
97. 97. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen induced arthritis in the BB rat: prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995;96:987-93.
98. 98. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ . In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40-gp39. J Exp Med 1993;178:1567-75.
99. 99. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261: 1328-30.
100. 100. Sioud M, Mellbye O, Förre Ö. Analysis of the NF-KB p65 subunit, fas antigen, fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Fxp Rheumatol 1998;16:125-34.
101. 101. Fujisawa Y, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, et al. Therapeutic effect of the anti-fas antibody on arthritis in HTLV-1 tax transgenic mice. J Clin Invest 1996;98:271-8.
102. 102. Förre Ö. Cyclosporine in rheumatoid arthritis: an overview. Clin Rheumatol 1995;14 Suppl 2:33-6.
103. 103. Förre Ö. The Norwegian Arthritis Study Group. Radiological evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37:1506-12.
104. 104. Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Förre Ö, Geidel H, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporine and parenteral gold. Br J Rheumatol 1998;37:874-82.
105. 105. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporine A. Arthritis Rheum 1996;39 6:1006-15.
106. 106. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-42.
107. 107. Randall EM. Rapamycin: FK506's fraternal twin or distant cousin? Immunol Today 1991;12:137-40.
108. 108. Herrmann M, Frangou GC, Kirschbaum B. Effects of Leflunomide on early T cell signaling and cell cycle commitment. Rheumatol Europe 1997;26 Suppl:16.
109. 109. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
110. 110. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate Mofetil. Immunol Rev 1993;136:5-28.
111. 111. McHugh SM, Rowland TL. Thalidomide and derivatives: Immunological investigations of tumor necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 1997;110:151-4.
112. 112. Bjørneboe O, Moen F, Nygaard H, Haavik TK, Svensson B. CPH-82 (Reumacon) versus auranofin (Ridaura). Scand J Rheumatol 1998;27:26-31.
113. 113. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.